News

 prime DX®: The New Era in Tumor Molecular Profiling!

The innovative prime DX® technology is compatible with both FFPET and PLASMA, offering a comprehensive approach to personalized cancer treatment. With 1,021 genes, including over 30 related to homologous recombination (HR), it provides physicians with a holistic perspective on therapeutic options associated with targeted therapy, immunotherapy, and chemotherapy.

The technology includes:

• Immunotherapy biomarkers: TMB, MSI, HLA, PD-L1, and LOH for treatment with PARP inhibitors
• Other immunotherapy biomarkers: HER2, FRα & CLDN 18.2
• 6 Agnostic Markers: NTRK1,2,3, RET Fusions, BRAFV600E mutation, and HER2 Amplification for targeted therapies and immunotherapies.

prime DX® is paving the way for a new era in personalized cancer treatment.

Learn More: https://genekor.com/services/prime/